[go: up one dir, main page]

WO2002060373A3 - Indole derivatives and their uses as heparanase inhibitors - Google Patents

Indole derivatives and their uses as heparanase inhibitors Download PDF

Info

Publication number
WO2002060373A3
WO2002060373A3 PCT/IL2002/000080 IL0200080W WO02060373A3 WO 2002060373 A3 WO2002060373 A3 WO 2002060373A3 IL 0200080 W IL0200080 W IL 0200080W WO 02060373 A3 WO02060373 A3 WO 02060373A3
Authority
WO
WIPO (PCT)
Prior art keywords
indole derivatives
heparanase inhibitors
heparanase
diseases
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2002/000080
Other languages
French (fr)
Other versions
WO2002060373A2 (en
Inventor
Maty Ayal-Hershkovitz
Daphna Miron
Ofra Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insight Strategy and Marketing Ltd
Original Assignee
Insight Strategy and Marketing Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insight Strategy and Marketing Ltd filed Critical Insight Strategy and Marketing Ltd
Priority to AU2002230056A priority Critical patent/AU2002230056A1/en
Publication of WO2002060373A2 publication Critical patent/WO2002060373A2/en
Publication of WO2002060373A3 publication Critical patent/WO2002060373A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides indole derivatives as heparanase inhibitors suitable for treatment of diseases and disorders caused by or associated with heparanase catalytic activity such as cancer, inflammatory disorders and autoimmune diseases.
PCT/IL2002/000080 2001-01-29 2002-01-29 Indole derivatives and their uses as heparanase inhibitors Ceased WO2002060373A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002230056A AU2002230056A1 (en) 2001-01-29 2002-01-29 Indole derivatives and their uses as heparanase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26430701P 2001-01-29 2001-01-29
US60/264,307 2001-01-29

Publications (2)

Publication Number Publication Date
WO2002060373A2 WO2002060373A2 (en) 2002-08-08
WO2002060373A3 true WO2002060373A3 (en) 2003-03-20

Family

ID=23005456

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2002/000080 Ceased WO2002060373A2 (en) 2001-01-29 2002-01-29 Indole derivatives and their uses as heparanase inhibitors

Country Status (2)

Country Link
AU (1) AU2002230056A1 (en)
WO (1) WO2002060373A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696231B2 (en) * 2001-10-30 2010-04-13 Laboratoires Serono Sa Oxindole hydrazide modulators of protein tyrosine phosphatases (PTPs)
GB0205256D0 (en) 2002-03-06 2002-04-17 Oxford Glycosciences Uk Ltd Novel compounds
DK2044026T3 (en) 2006-06-22 2014-06-30 Prana Biotechnology Ltd PROCEDURES FOR THE TREATMENT OF CEREBRAL GLIOMA TUMOR
JP5404406B2 (en) * 2006-10-20 2014-01-29 ジ オーストラリアン ナショナル ユニバーシティ Inhibition of extracellular matrix degradation
CN104370799B (en) * 2014-11-27 2017-07-21 天津坤健生物制药有限公司 A kind of 3 oxo diazanyl substituted indole ketones derivants and preparation method and application
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
JP2020503377A (en) 2016-12-13 2020-01-30 ベータ セラピューティクス プロプライアタリー リミティド Heparanase inhibitors and uses thereof
EP3381906A1 (en) 2017-03-27 2018-10-03 Leadiant Biosciences SA Compounds for use as heparanase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
US5919809A (en) * 1989-04-18 1999-07-06 Pfizer Inc. 3-substituted-2-oxindole derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
US5919809A (en) * 1989-04-18 1999-07-06 Pfizer Inc. 3-substituted-2-oxindole derivatives
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby

Also Published As

Publication number Publication date
WO2002060373A2 (en) 2002-08-08
AU2002230056A1 (en) 2002-08-12

Similar Documents

Publication Publication Date Title
WO2002060374A3 (en) Benz-1,3-azole derivatives and their uses as heparanase inhibitors
WO2005074375A3 (en) Heparanase inhibitors and uses thereof
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2002060867A3 (en) Carbazole derivatives and their uses as heparanase inhibitors
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2005007141A3 (en) Ubiquitin ligase inhibitors and methods related thereto
WO2005046603A3 (en) Pyridine compounds
WO2001087328A3 (en) Interleukin-1 inhibitors in the treatment of diseases
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
IL172942A0 (en) Pyrazoloisoquinoline derivatives as kinase inhibitors
WO2003080582A3 (en) Fredericamycin derivatives
NO20035025D0 (en) Use of osteopontin for treatment and / or prevention of neurological disorders
WO2005053609A3 (en) Methods of nad+-dependent deacetylase inhibitors
WO2002060375A3 (en) Diphenyl ether derivatives and their uses as heparanase inhibitors
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
WO2004031105A3 (en) Use of a33 antigens and jam-it
WO2001098279A3 (en) Bis-arylsulfones
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
NO20054913L (en) Use of clustein for the treatment and / or prevention of peripheral neurological disorders
WO2006075095A3 (en) Use of purine derivatives as hsp90 protein inhibitors and for treatment of cancer
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
WO2002060373A3 (en) Indole derivatives and their uses as heparanase inhibitors
WO2004032864A3 (en) X-nitro compounds, pharmaceutical compositions thereof and uses therof
WO2007051785A3 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP